Vitamin D as adjunctive host-directed therapy in tuberculosis: A systematic review

Open Forum Infectious Diseases

Volumn 3, Issue 3, 2016, Pages

  Wallis, Robert S ^a,b,c   Zumla, Alimuddin ^d  

^a AURUM INSTITUTE   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical trial; Host directed therapy; Tuberculosis; Vitamin D

Indexed keywords

COLECALCIFEROL; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; FOLLOW UP; GENETIC BACKGROUND; GENETIC POLYMORPHISM; HEMOPTYSIS; HUMAN; PRIORITY JOURNAL; SPIROMETRY; SPUTUM CULTURE; SUN EXPOSURE; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TUBERCULOSIS; VITAMIN D DEFICIENCY;

EID: 85015989469     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofw151     Document Type: Article

References (32)

1. Coussens AK, Martineau AR, Wilkinson RJ. Anti-inflammatory and antimicrobial actions of vitamin D in combating TB/HIV. Scientifica (Cairo) 2014; 2014: 903680.
2. Wilkinson RJ, Llewelyn M, Toossi Z, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 2000; 355:618-21.
3. Orkin C, Wohl DA, Williams A, Deckx H. Vitamin D deficiency in HIV: a shadow on long-term management? AIDS Rev 2014; 16:59-74.
4. Martineau AR, Nhamoyebonde S, Oni T, et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci U S A 2011; 108:19013-7.
5. Koh GC, Hawthorne G, Turner AM, et al. Tuberculosis incidence correlates with sunshine: an ecological 28-year time series study. PLoS One 2013; 8:e57752.
6. Maclachlan JH, Lavender CJ, Cowie BC. Effect of latitude on seasonality of tuberculosis, Australia, 2002-2011. Emerg Infect Dis 2012; 18:1879-81.
7. Crowle A, Ross ER, May MH. Inhibition by 1, 25 (OH)2 vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages. Infect Immun 1987; 55:2945-50.
8. Rockett KA, Brookes R, Udalova I, et al. 1, 25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infect Immun 1998; 66:5314-21.
9. Martineau AR, Wilkinson KA, Newton SM, et al. IFN-gamma-and TNFindependent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol 2007; 178:7190-8.
10. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311:1770-3.
11. Yuk JM, Shin DM, Lee HM, et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009; 6:231-43.
12. Neville F, Cahuzac M, Konovalov O, et al. Lipid headgroup discrimination by antimicrobial peptide LL-37: insight into mechanism of action. Biophys J 2006; 90:1275-87.
13. Martineau AR, Wilkinson RJ, Wilkinson KA, et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med 2007; 176:208-13.
14. Martineau AR, Newton SM, Wilkinson KA, et al. Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest 2007; 117:1988-94.
15. Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 2008; 14:5967-76.
16. Wallis RS, Wang C, Meyer D, Thomas N. Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLoS One 2013; 8:e71116.
17. Wallis RS, Peppard T, Hermann D. Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update. PLoS One 2015; 10:e0125403.
18. Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrugresistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med 2015; 3:201-9.
19. Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 2015; 60:1361-7.
20. Altman DG. Practical Statistics for Medical Research. London: Chapman and Hall; 1991.
21. Ralph AP, Waramori G, Pontororing GJ, et al. L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebocontrolled trial. PLoS One 2013; 8:e70032.
22. Martineau AR, Timms PM, Bothamley GH, et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a doubleblind randomised controlled trial. Lancet 2011; 377:242-50.
23. Wejse C, Gomes VF, Rabna P, et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2009; 179:843-50.
24. Daley P, Jagannathan V, John KR, et al. Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2015; 15:528-34.
25. Salahuddin N, Ali F, Hasan Z, et al. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis'. BMC Infect Dis 2013; 13:22.
26. Tukvadze N, Sanikidze E, Kipiani M, et al. High-dose vitamin D3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial. Am J Clin Nutr 2015; 102:1059-69.
27. Mily A, Rekha RS, Kamal SM, et al. Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial. PLoS One 2015; 10:e0138340.
28. Nursyam EW, Amin Z, Rumende CM. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med Indones 2006; 38:3-5.
29. Coussens AK, Wilkinson RJ, Hanifa Y, et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A 2012; 109:15449-54.
30. Wejse C, Gustafson P, Nielsen J, et al. TBscore: signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand J Infect Dis 2008; 40:111-20.
31. Steinmann J, Halldorsson S, Agerberth B, Gudmundsson GH. Phenylbutyrate induces antimicrobial peptide expression. Antimicrob Agents Chemother 2009; 53:5127-33.
32. Raqib R, Mily A, Kamal SM, et al. Clinical trial of oral phenylbutyrate and vitamin D adjunctive therapy in pulmonary tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2014; 18: S233-4.